Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
10 clusters · 40 sources · 63 days · First seen · Last updated
Global RSV prevention and immunization efforts
Overview
Public health authorities are implementing expanded strategies to combat Respiratory Syncytial Virus (RSV) for the 2026–2027 season. In the United Arab Emirates, the Ministry of Health and Prevention has broadened its respiratory disease awareness campaign to include RSV alongside influenza, targeting high-risk groups like pregnant women and older adults. In Dubai, the Dubai Health Authority has issued updated clinical guidelines requiring healthcare providers to verify vaccination status during clinical visits, specifically prioritizing individuals with chronic cardiac, pulmonary, renal, liver, or neurodevelopmental diseases, as well as pilgrims for Hajj and Umrah. Clinical data continues to support various interventions. In Austria, research from the Graz Women’s and Children’s Clinics confirmed that RSV immunization significantly reduces infant hospitalization risk, showing a 77 percent reduction in risk compared to non-immunized infants. However, in Vienna, medical professionals noted that while some vaccinations are free, RSV immunization currently requires out-of-pocket payment, which is a concern for oncology patients with weakened immune systems. In Poland, Professor Piotr Rzymski stated that RSV vaccination protects against severe lower respiratory tract infections for at least three infectious seasons. New research published in The Lancet suggests that RSV immunization, specifically via the monoclonal antibody Nirsevimab, may provide secondary protection against invasive pneumococcal infections, with a study in France observing a 36 percent decrease in such hospitalizations among children. In Italy, experts are calling for RSV vaccines to be included in the National Vaccination Prevention Plan to ensure uniform access, noting that the virus causes significant annual mortality among those aged 60 and over. In Spain, a multicenter study in Andalusia involving the University Hospital of Jaén and eight other pediatric hospitals has confirmed that nirsevimab significantly reduces RSV-related hospitalizations in infants. Published in the journal Pediatrics, the research indicates that protective benefits extend into the child’s second year of life.
Entities
Graz Children's Clinic · Dominican Republic · Respiratory Syncytial Virus · World Health Organization · United Arab Emirates
Timeline
-
[HEALTH] 2 sourcesAndalusian study shows monoclonal antibody reduces RSV hospitalizations
An Andalusian study reveals that the monoclonal antibody nirsevimab reduces RSV-related hospitalizations in infants, with protective benefits lasting into their second year of life.
-
[HEALTH] 2 sourcesRSV immunization linked to reduced pneumococcal hospitalizations
A French study indicates RSV immunization with Nirsevimab may reduce pneumococcal hospitalizations in infants by 36%, while global vaccination efforts show significant declines in RSV-related hospitalizations.
-
[HEALTH] 19 sourcesRespiratory Syncytial Virus (RSV) awareness campaign highlights risks to vulnerable groups
Health experts emphasize the risks of Respiratory Syncytial Virus (RSV) to infants and the elderly, advocating for increased vaccination awareness and national immunization programs in Italy.
-
[HEALTH] 2 sourcesRSV vaccination provides protection for at least three seasons, expert says
Expert Piotr Rzymski reports that RSV vaccines offer protection for at least three seasons and warns of increased heart attack and stroke risks following severe infections.
-
[HEALTH] 4 sourcesRSV immunization significantly reduces infant hospitalizations in Austria
A Graz study shows RSV immunization reduces infant hospitalizations by 77 percent, while experts urge cancer patients to maintain seasonal vaccinations to avoid treatment delays.
-
[HEALTH] 2 sourcesRSV prevention emphasized for infants ahead of winter season
Experts advise parents to prepare for the RSV season by considering antibody injections for infants to prevent severe complications like pneumonia and bronchiolitis.
-
[HEALTH] 3 sourcesRSV prevention strategies show significant reduction in infant hospitalizations
Medical studies and new treatments highlight RSV prevention, noting that maternal vaccination can reduce infant hospitalizations by 74% and new antibodies can lower RSV hospitalization risks by over 84%.
-
[HEALTH] 2 sourcesMedical societies propose RSV protection strategy for infants in Dominican Republic
Medical societies in the Dominican Republic have proposed a combined strategy of maternal vaccination and monoclonal antibodies to protect newborns and high-risk infants from respiratory syncytial virus (RSV).
-
[HEALTH] 2 sourcesRSV prevention strategies expanded for infants and pregnant women
New prevention strategies for RSV-related bronchiolitis include maternal vaccination or monoclonal antibody injections for infants to reduce the risk of severe respiratory infection.
-
[HEALTH] 2 sourcesUAE expands respiratory disease campaign to include RSV
The UAE has expanded its seasonal respiratory disease campaign to include RSV vaccinations, targeting high-risk groups like pregnant women, the elderly, and those with chronic illnesses.
Sources
aend.de · bezirksjournal.at · bokuennews.com · bosa.co.kr · bourgogne-franche-comte.ars.sante.fr · cagliarilivemagazine.it · cinquecolonne.it · clicmedicina.it · cn24tv.it · codirp.it · denik.cz · diariodesalud.com.do · dietrolanotizia.it · dubaiweek.ae · egnews.it · forchecaudine.it · geekweek.interia.pl · gesundheitsverbund.at · gulfnews.com · horajaen.com · ilfattonisseno.it · ilsannioquotidiano.it · immedicohospitalario.es · infosaludrd.com · insalutenews.it · lacronaca24.it · lamilano.it · ledauphine.com · lsdmagazine.com · m.sportalkorea.com · mantovauno.it · naukawpolsce.pap.pl · notizie.it · notiziedi.it · quotidianodibari.it · rynekzdrowia.pl · sportschosun.com · technoblitz.it · vivirediciones.es · wochentlich.de
This summary has been updated 13 times: see revision history